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Abstract. Mutations in the progranulin gene (GRN), causative for Frontotemporal Lobar Degeneration with ubiquitin-
immunoreactive neuronal inclusions (FTLD-U), could also be associated with Alzheimer’s disease (AD). The influence of GRN
genetic variability on susceptibility to AD and on expression levels in a series of neuropathologically-confirmed AD patients
as well as in peripheral mononuclear cells (PBMC) and in cells isolated from cerebrospinal fluid (CSF) was investigated. An
association study of rs9897526 and rs5848 was carried out in an Italian population and in a replication population of European
American patients and controls. None of the variants tested act as unequivocal susceptibility factor in both populations although
rs9897526 anticipated the onset of the disease in the Italian population. GRN expression in the parietal lobe of AD cases showed
a 0.76-fold decrease compared with controls (1.31 ± 0.07 versus 1.73 ± 0.12, P = 0.0025). Patients carrying the rs5848 TT
genotype had the lowest GRN expression levels (0.96 ± 0.12, P = 0.014). Despite no significant differences were found in
the relative PBMC and CSF GRN expression in patients compared to controls, stratifying patients according to the presence of
rs5848 T allele, a 0.57-fold decrease in GRN mRNA levels over C carriers was found in PBMC (1.22± 0.23 versus 0.70 ± 0.12,
P = 0.04). Similarly to data obtained in brain samples, patients carrying the TT genotype showed the lowest GRN mRNA levels
(TT = 0.46 ± 0.14, CC = 1.22 ± 0.23; P = 0.013). These data argue against a direct role of GRN as a susceptibility factor for
sporadic AD but support a role of GRN as a disease-modifying gene, possibly contributing to the failure of neuronal survival.
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INTRODUCTION
Alzheimer’s disease (AD) is the most common form
of primary degenerative dementia with a complex eti-
ology and a strong genetic component affecting ap-
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proximately 15 million people worldwide [1]. The
only well-confirmed genetic risk factor for sporadic
AD is the apolipoprotein E (APOE) gene. Many oth-
er functional candidate genes coding for molecules in-
volved in the pathogenic pathway of AD were pro-
posed. Among these, Progranulin (GRN) could be con-
sidered a strong biological candidate gene as it has at-
tracted significant attention in the scientific community
following the recent discoveries of mutations causative
for Frontotemporal Lobar Degeneration with ubiquitin-
immunoreactive neuronal inclusions (FTLD-U) [2,3].
A number of pathogenic GRN variants are predicted
to result in a premature termination codon, leading to
the degradation of the mutant mRNA through the pro-
cess of nonsense mediated decay, resulting in a null
allele [2].
GRN is a multifunctional secreted growth factor en-
coded by GRN gene on chromosome 17q21. GRN en-
codes for a 593 amino acid glycoprotein containing 7.5
tandem repeats of 12 cysteinyl granulin motifs. Pro-
granulin and the various granulin peptides derived by
elastase cleavage are implicated in a range of biolog-
ical functions [4]. Progranulin is widely expressed in
several tissues and has been implicated in development,
wound repair, inflammation, and tumorigenesis [5]. It
is highly expressed in neurons of the cerebral cortex,
the hippocampus, and the cerebellum but its role in the
central nervous system (CNS) has not been investigated
extensively [6].
Interestingly, GRN expression has been found in-
creased in activated microglia as well as in peripheral
blood in AD suggesting a potential role in this patholo-
gy [2,7]. Furthermore, several patients carrying muta-
tions in GRN exhibited a clinical presentation indistin-
guishable from AD [8]. Recently the same authors in-
vestigated the genetic variability within the GRN locus
in a Belgian population of AD patients and found GRN
haplotypes associated with increased risk for AD [9].
Furthermore, Cortini and colleagues [10] reported a
novel putative GRN mutation leading to an amino acidic
substitution in an Italian patient with clinical AD.
In the present study, GRN mutation scanning was
performed in a cohort of Italian patients and an asso-
ciation analysis was performed for two frequent vari-
ants, rs9897526 G > A and rs5848 C > T , to test
whether GRN genetic variability contributes to the sus-
ceptibility for AD in the Italian population. Results
were confirmed in a second replication population.
In addition, a wide transcriptional analysis was car-
ried out in the parietal lobe of 68 neuropathologically-
confirmed AD cases and 43 controls as well as in pe-
ripheral blood mononuclear cells (PBMC) and in cells
isolated from cerebrospinal fluid (CSF), to investigate
the expression profile of GRN and the possible influence
of the common variants considered on mRNA levels.
SUBJECTS AND METHODS
Subjects
Two set of samples were included in this study. The
first series consisted of 355 patients with AD consec-
utively recruited at the Alzheimer Units of Ospedale
Maggiore Policlinico (Milan) and Ospedale L. Sacco
(Milan). All patients underwent a standard battery of
examinations, including medical history, physical and
neurological examination, screening laboratory tests,
neurocognitive evaluation, brain magnetic resonance
imaging (MRI) or computed tomography (CT), and,
if indicated, positron emission computed tomography
(PET). Dementia severity was assessed by the Clinical
Dementia Rating (CDR) and the Mini Mental Scale Ex-
amination (MMSE). Disease duration was defined as
the time in years between the first symptoms (by histo-
ry) and the clinical diagnosis. The presence of signif-
icant vascular brain damage was excluded (Hachinski
Ischemic Score < 4). The diagnosis of probable AD
was made by exclusion according to NINCDS-ADRDA
criteria [11]. Fifty AD patients had an early onset of
disease (EOAD; < 65 years) whereas remainders had
a late onset (LOAD; 65 years).
The control group (CON) consisted of 377 subjects
matched for ethnic background, age, and gender with-
out memory impairment (MMSE> 28) and psychobe-
havioral complaints. The age of controls did not sig-
nificantly differ from that of patients (P > 0.05). All
patients or their caregivers gave informed consent for
this study.
The second series consisted of an American set of
samples collected through the Alzheimer’s Disease Re-
search Center (ADRC) at Washington University. Cas-
es were diagnosed using the NINCS-ADRDA criteria,
slightly modified to include AD as a diagnosis for in-
dividuals aged > 90 years [11,12]. A total of 355 un-
related AD cases were recruited for the study. DNA
from 343 age- and sex-matched non-demented controls
aged > 60 years at assessment were obtained through
the ADRC.
Sixty-eight out of 355 patients as well 43 out of 343
controls included in the American series, underwent
neuropathological analysis, which confirmed the clini-
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Table 1
Characteristics of patients and controls for both populations
CON AD US CON US AD
Number of subjects 377 355 343 355
Gender (M:F) 121:256 105:250 131:212 128:227
Mean age, years ± S.E.M. 73.56± 0.58 76.50± 0.35 78.73± 0.47 83.89± 0.37
Mean age at onset, years ± S.E.M. 73.03± 0.58 76.69± 0.39
Mean disease duration, years ± S.E.M. 3.17± 0.22 8.21± 0.25
ApoEε4 carriers (%) 57 (15) 147 (41)* 59 (21) 189 (56)*
∗P < 0.001, AD versus CON (OR: 4.35; CI: 3.06–6.19).
cal diagnosis. Transcriptional analysis was carried out
from RNA extracted by the parietal lobe of these indi-
viduals. All subjects included in the replication popu-
lation were European Americans. All patients or their
caregivers gave informed consent for this study. In-
formation about cases and controls are summarized in
Table 1.
DNA isolation and ApoE genotyping
High-molecular weight DNA was isolated from
whole blood using a Flexigene Kit (Qiagen, Hildren,
Gemany), as described by the manufacturer. For the
Italian sample, DNA was amplified using specific
primers and then digested with HhaI, as previously de-
scribed [13]. For the U.S. sample, APOE genotyping
was performed using a Taqman assay (purchased from
Applied Biosystems, ABI).
Direct sequencing
The entire open reading frame with the exon-intron
boundaries of GRN was sequenced in a subgroup of 50
patients with AD as well as in 50 age-matched controls
using specific primers, as previously described [14].
Briefly, each PCR was carried out in 50 µl total volume
containing 25 ng genomic DNA, 12.5 pmol of each
specific primers, 0.6µM of each dATP, dTTP, dCTP and
dGTP, 1U Taq DNA polymerase (ABI). Amplification
conditions consisted of an initial denaturation step at
94◦C for 5 min followed by 38 cycles of 94◦C for
30 sec, Tm for 30 sec and 72◦C for 45 sec, and a final
extension step of 72◦C for 10 min.
Fragments were purified using the ExoSAP-IT Kit
(USB, USA), according to instructions of the manufac-
turer, and then direct sequencing was performed with
an ABI PRISM 3100 gene analyzer (ABI). Sequenc-
ing PCR was carried out in 20 µl total volume contain-
ing 1 µl BigDye Terminator v3.1 (ABI), 1.6 pmol of
each primer and water to reach the final volume. Ther-
mocycling consisted of 25 cycles of 96◦C for 30 sec, 50
for 20 sec and 60◦C 3 min. Sequences were analyzed
with the Seqscape software.
Genotyping assays
Allelic variants with a frequency> 10% were test-
ed for association in the Italian series were analyzed
by using TaqMan methodology. Each Taqman 5’-
nuclease assay employed 25 ng of genomic DNA
as template. Assay-on-demand products, ABI assay
IDs: C 2548248 10, C 7452046 20, were used for
rs9897526 and rs5848 genotyping respectively. Probes
specific for these variants were labeled with 6-FAM
and VIC as reporter dyes and MGB-NFQ (ABI) as
quencher. All the assays were performed in 20 µl re-
actions in 96-well plates using an ABI PRISM 7000
instrument (ABI) as previously described [15].
Genotyping for rs5848 in the US series was per-
formed using matrix assisted laser desorption/ioniza-
tion time-of-light (MALDI-TOF) mass spectrometry
(Sequenom). PCR primers and primer extension assays
were designed by using SPECTROGEN software (Se-
quenom). SNP assays were designed to generate ex-
tension products of different masses resulting in geno-
type dependent peak appearance [16]. Genotyping for
rs9897526 in the US series was done using TaqMan as
described above.
RNA isolation and expression analysis
Total RNA from the parietal lobe of 68 neuropatholo-
gically-confirmed AD cases and 43 controls from the
US series was extracted using the Tissue Kit and
RNeasy Lipid Tissue kit (http://www.qiagen.com). cD-
NA was obtained from total RNA using the High Ca-
pacity cDNA Archive Kit.
Total RNA from PBMC was obtained from 26 pa-
tients (17 females, mean age: 73.42± 1.93 and 9 males
, mean age 77.57 ± 1.67) and 27 control subjects (16
females, mean age: 70.13 ± 4.20 and 11 males, mean
age: 69.29 ± 3.20) from the Italian series carrying
different genotypes.
Additionally, total RNA from cells isolated from
CSF was available from 25 subjects of the Italian se-
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ries: 17 patients (9 males, mean age 69.75± 4.5 and 8
females, mean age: 75.5± 3.50) and 8 control subjects
(4 males, mean age 70.50± 0.20 and 4 females, mean
age 74.00± 0.89).
RNA purity was measured by optical density and
only samples with an OD 260/280 ratio of 1.8 to 2 and
an OD 260/230 of 1.8 or greater were used. Then,
to confirm the lack of gDNA, PCR was carried out
using primers located in different consecutives exons
of actin housekeeping gene. cDNA was detected by
the presence of an amplicon of 250 bp, whereas gDNA,
characterized by the presence of a 444 bp fragment,
was absent. In addition, RNA integrity was confirmed
by quantified cDNA levels for GAPDH (2 different
assays, located in different regions of the gene), B2M
and cyclophilin A.
GRN expression levels in parietal lobe were mea-
sured by using a custom TaqMan assay for GRN exon
12 (primers and probes available upon request) using
GAPDH as endogenous control. Each real-time PCR
run included within-plate duplicates and each experi-
ment was performed twice for each sample. Correction
for sample-to-sample variation was done by simulta-
neously amplifying GAPDH as a reference. Real-time
data were analyzed using the comparative Ct method.
The Ct values of each sample were normalized with the
Ct value for the housekeeping gene, GAPDH, and were
corrected for the PCR efficiency of each assay,although
the efficiency of all reactions was close to 100%. Only
samples with an s.e. < 10% were analyzed.
Total RNA from PBMC was reverse-transcribed us-
ing the Ready to go kit (USB, USA). Subsequently,
the relative expression of GRN was measured by quan-
titative RT-PCR using premade TaqMan gene expres-
sion assays developed in the meantime (ABI, Assay
ID: Hs00173570 m1). This custom-made assay under-
went rigorous quality control testing, including mass
spectrometry to verify the sequence, and further testing
ensuring proper formulation of probe and primer mix.
As an endogenous control for sample normalization,
18S rRNA was used (ABI, Assay ID: HS99999901 s1).
The relative quantity of RNA was measured in dupli-
cate by the ∆∆CT method relative to the data from a
control subject [17].
Qualitative transcriptional analysis of rs9897526
has been performed through cDNA amplification
of exons 2-7 by using specific primers (forward:
5’-GCCACTCCTGCATCTTTACC-3’; reverse: 5’-
TTCTCCTTGGAGAGGCACTT-3’). Fragments (wild
type length: 586 bp) were visualized by agarose gel-
electrophoresis stained with ethidium bhromide.
Statistical analysis
Allelic and genotypic frequencies were obtained by
direct counting. Haploview v4.1 software was used to
test for Hardy Weinberg Equilibrium (HWE), Linkage
Disequilibrium (LD), and for differences in allele dis-
tribution between cases and controls. Non-parametric
Mann-Whitney Rank sum test was used for differences
related to age at onset of disease in different genotype
carriers. According to the Bonferroni’s correction, the
threshold for significance was set at P < 0.025. One
way Anova test, including Holm-Sidak for multiple
comparisons, was performed for differences related to
mRNA levels.
In the neuropathological series,GRN mRNA levels
were compared using the Kruskall-Wallis test. Step-
wise discriminant analysis did not detect any important
covariant (age, gender, APOE status).
RESULTS
Genetic analysis
Direct sequencing of GRN in 50 Italian AD sam-
ples did not show any novel mutation but led to the
identification of several known common variants pre-
viously reported (Table 2). Among these, rs9897526,
which is located 21 bp downstream of the GRN intron
2 splice donor site and rs5848, located in the 3’UTR
region, showed a minor allele frequency (MAF)> 10%
and were subsequently tested for association with AD.
Pairwise LD analysis computed with Haploview soft-
ware indicated no LD between rs9897526 and rs5848
(D’ = 0.40) thus no haplotype blocks and markers
combinations were highlighted according to the defini-
tion by Gabriel and colleagues [18], as implemented in
Haploview v4.1.
Both SNPs were in HWE in cases and controls for
both datasets. A tendency to an increased frequency
of rs5848T allele was found in patients as compared
with controls although it hardly reaches the significant
threshold required according to the Bonferroni’s cor-
rection (rs5848 MAF: 34.5% versus 29.0% in patients
as compared with controls, P = 0.025). Allelic and
genotype frequencies did not differ between patients
and controls for rs9897526 (MAF: 14.4% versus 12.2%
in patients as compared with controls, P  0.05). Data
were replicated in a second independent series from
US (rs5848 MAF: 30.0% versus 27.9% in cases and
controls respectively, rs9897526 MAF: 12.7% versus
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Table 2
PGRN allelic variants identified in Italian patients
Mutation Genomica Predicted proteinb Location rs number
g.95914delC 5’-untranslated region rs17523519
g.96286insG 5’-untranslated region rs11398947
g.100165C>T p.Asp33Asp EX1
g.100169G>A p.Gly35Arg EX1
g.100460G>A IVS2
g.100474G>A IVS2 rs9897526
g.101084insGTCA IVS3 rs34424835
g.101164T>C p.Asp128Asp EX4 rs25646
g.101266G>A IVS4 rs850713
g.102072G>A IVS7
g.103778C>T 3’UTR rs5848
aNumbering relative to the reverse complement of GenBank accession number
AC003043.1 and starting at nucleotide 1.
bNumbering according to GenPept accession number NP 002078.1.
Table 3
Allelic and genotype frequencies (%) in AD compared with age-matched controls in the two study
samples
SNP n Genotype % (n) Allele % (n) p-value
Italian series
Rs9897526 GG GA AA G A
Controls 377 77.7 (293) 20.2 (76) 2.1 (8) 87.8 (662) 12.2 (92) 0.10
Cases 355 72.7 (258) 25.9 (92) 1.4 (5) 85.6 (608) 14.4 (102)
Rs5848 CC CT TT C T
Controls 377 51.0 (194) 39.0 (147) 10.0 (36) 71.0 (535) 29.0 (219) 0.025
Cases 355 43.1 (153) 44.9 (159) 12.0 (43) 65.5 (465) 34.5 (245)
US series
Rs9897526 GG GA AA G A
Controls 343 76.0 (261) 22.4 (77) 1.5 (5) 87.3 (599) 12.7 (87) 0.53
Cases 355 74.1 (263) 23.7 (84) 2.2 (8) 85.9 (610) 14.1 (100)
Rs5848 CC CT TT C T
Controls 302 52.0 (157) 40.0 (121) 8.0 (24) 72.1 (435) 27.9 (169) 0.52
Cases 329 49.2 (162) 41.3 (136) 9.5 (31) 70.0 (460) 30.0 (198)
14.1% in cases as compared with controls; P > 0.05,
Table 3).
No association with APOE status or gender was
found in both populations considering each SNP.
In the Italian series, cases carrying the rs9897526A
variant had a significantly earlier age at disease onset
compared with patients carrying theG allele (mean age
70.12 ± 1.18, n = 71 versus 74.32 ± 0.69, n = 173
respectively, P = 0.002) whereas no influence on age
at onset has been found according to the rs5848 status.
Expression analysis
GRN expression in the parietal lobe of 68 neuropath-
ologically-confirmed AD cases showed a 0.76-fold de-
crease as compared with controls (1.31 ± 0.07 versus
1.73 ± 0.12, P = 0.0025, Fig. 1A). Moreover, among
cases, individuals carrying the TT genotype presented
the lowest GRN expression levels (0.96 ± 0.12, P =
0.014, Fig. 1B). On the contrary, theP -value for associ-
ation of rs5848 with GRN expression in controls’ brain
was 0.922. The GRN mRNA mean level in controls
carrying the rs5848 T allele was 1.62 and for rs5848C
carriers was 1.63.
Although no significant differences were found in the
relative PBMC and CSF GRN expression in patients as
compared with controls in the independent AD Italian
series (data not shown), stratifying patients according
to the presence of rs5848T allele, a statistically sig-
nificant 0.57-fold decrease in GRN mRNA levels over
C carriers was found in PBMC (0.70 ± 0.12 versus
1.22 ± 0.23, P = 0.04, Fig. 2). This effect was likely
dose-dependent, as patients carrying the TT genotype
showed the lowest GRN mRNA levels in PBMC, 0.38
fold decrease over CC carriers (TT = 0.46± 0.14; CC
= 1.22± 0.23, P = 0.013, Fig. 2). This tendency was
608 C. Fenoglio et al. / Rs5848 SNP Decreases GRN mRNA Levels in AD Brain
(A) 
0,00
0,50
1,00
1,50
2,00
G
R
N
m
R
N
A
le
v
e
ls
* P=0,0025
AD CON
*
(B) 
0,00
0,50
1,00
1,50
2,00
G
R
N
m
R
N
A
le
v
e
ls
CC CT TT
*
* P=0,014
Fig. 1. A) GRN expression levels in parietal lobe from patients and controls B) association of rs5848 with GRN relative mRNA expression.
Values are expressed as mean relative mRNA levels ± S.E.M. Kruskall-Wallis test was used for differences related to the mRNA levels in rs5848
genotype carriers. Y-Axis represents the relative expression level taking an arbitrary reference sample as 1.
not significant in controls (CC = 1.09 ± 0.22 versus
CT/TT = 0.84 ± 0.16). Similarly, considering GRN
expression levels in cells isolated from CSF, the same
effect was observed although the significance threshold
was not reached, probably due to the small sample size
(data not shown).
Conversely, real time PCR showed no difference in
the rate of mRNA levels in carriers of rs9897526 A
compared with non-carriers (data not shown). In addi-
tion, a qualitative agarose gel-electrophoresis of GRN
PCR amplicons obtained from first-strand cDNA pre-
pared from PBMC revealed no differences in the tran-
script length comparing subjects carrying different al-
leles (Fig. 3).
DISCUSSION
According to our results, GRN rs9897526and rs5848
or SNPs in high LD with these variants do not act as
susceptibility factors for AD, but rs5848 polymorphism
is consistently associated with decreased GRN mRNA
levels in the parietal lobe of patients with AD. This
effect was observed also in PBMC from patients.
The association study revealed no significant differ-
ences in the distribution of rs9897526 and rs5848 in
cases and controls beneath a tendency towards an in-
creased frequency of rs5848T allele was observed in
the Italian AD population. Data were replicated in
an independent American set of samples, thus arguing
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Fig. 2. Association of rs5848 with GRN mRNA expression in PBMC from AD patients. Values are expressed as mean relative mRNA levels ±
S.E.M. One way Anova test, including Holm-Sidak for multiple comparisons was performed for differences related to the mRNA levels in rs5848
genotype carriers. Y-Axis represents the relative expression level taking an arbitrary reference sample as 1.
586 bp
1 2 3 4
Fig. 3. Transcript analysis of rs9897526 variant. Agarose gel-ele-
ctrophoresis of GRN amplicon obtained from PBMC cDNA from
subjects carrying different genotypes: GG lane 2, GA lane 3, AA lane
4. The expected transcript length of GRN cDNA exon 2-7 (586 bp)
does not differ according to rs9897526 status. DNA weight marker,
lane 1: VIII (Boehringer-Roche).
against a direct role of these common variants in sus-
ceptibility to AD. On the other hand, some recent find-
ings suggested a role for rs5848 in the risk for FTLD-
U, increasing the OR to develop FTLD-U for carriers
homozygous for the minor T-allele up to 3 times [19].
The apparent negative association found in AD could
be due to different pathogenic mechanisms underlying
different neurodegenerative diseases, however, the dif-
ference observed in rs5848 distribution in the Italian
AD population suggests that further replication studies
are required to drawn definitive conclusions.
Interestingly, GRN expression was decreased in the
parietal lobe of AD subjects. A similar trend was found
in cells from CSF in the independent Italian series, al-
though significance levels were not reached, possibly
due to the small number of CSF samples studied. On
the contrary, no significant differences were found in
the relative PBMC GRN expression levels in patients
compared with controls. These results did not con-
firm findings from Coppola and colleagues [7] who re-
ported increased GRN expression levels in PBMC of
patients affected from different neurodegenerative dis-
orders, suggesting whole blood gene expression pro-
file as a suitable surrogate for gene expression in the
CNS. This discrepancy could be explained by sever-
al reasons: first, the large gene expression study from
Coppola et al. [7] was performed using microarrays on
PBMC without any further validation which is usually
performed, since concerns regarding the reliability and
comparability of microarray data have been raised [20–
22]. Herein, the TaqMan technology, commonly used
for validation and comparison of gene expression in mi-
croarray quality control studies [23–25] and considered
the gold standard for gene expression measurement,
was performed.
Moreover, whole blood gene expression profile, al-
though sharing significant similarities with that of the
CNS, could not be representative for all brain regions as
evinced from the hierarchical clustering results for gene
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expression data from whole blood and several CNS tis-
sue including the parietal lobe [26]. Recent evidence
described clinical parietal lobe features in many cases
of FTLD with a positive family history together with
histopathologic evidence of significant parietal lobe in-
volvement in association with GRN mutations [27–32].
According to these data it is tempting to consider pari-
etal lobe deficits as salient feature of the progranulin
phenotype, thus an imbalance of GRN expression in
parietal lobe of AD patients would be conceivable.
In the present study, GRN expression in the pari-
etal lobe of patients with AD was strongly influenced
by the presence of rs5848T allele. A significant de-
crease of GRN mRNA levels was observed in AD cases
carrying the polymorphic T allele as compared with
non-carriers. Similar results were obtained in PBMC
as well as in cells isolated from the CSF, although the
small sample size did not allow a definitive conclusion.
These data are in accordance with previous evidence
suggesting that rs5848 is implicated in differential ex-
pression of GRN in a database-mining experiment [33].
Moreover, Rademakers and colleagues [19] supported
the homozygosity of rs5848T allele as a major risk fac-
tor for FTLD-U through a decrease in levels of func-
tional GRN. Haplo-insufficiency was predicted by the
authors to result from increased suppression of GRN
translation through altered micro (mi)RNA regulation,
since rs5848 resulted to be located within a predict-
ed binding-site for the human specific miR-659, which
would contribute to translational repression.
According to our results, rs5848 variant showed an
influence on GRN mRNA levels. This effect could be
due to different translational regulation mechanisms by
miRNAs peculiar of AD pathology, which in the case
of rs5848 could have the same effect in reducing GRN
expression levels.
The reduction of available GRN could be related with
neurodegeneration, as most GRN mutations resulting in
a reduction of the GRN protein levels due to nonsense
mediated mRNA decay and consequently reduced GRN
levels are causative for neurodegenerative processes [2,
3].
Recently several missense mutations resulted associ-
ated, through different molecular mechanisms, to a sig-
nificantly reduced secretion of the protein [34]. Thus,
apparently all GRN mutations cause reduced protein
expression levels or secretion [34,35]. Furthermore
Ghidoni and collaborators [36] analyzed GRN plasma
and CSF levels in FTLD and demonstrated that GRN
is strongly reduced both in plasma and CSF of affected
and unaffected subjects carrying mutations in the gene,
confirming the initial reports of low levels of GRN due
to the effect of GRN mutations.
Although the exact effects of GRN in the CNS re-
main to be established, emerging evidence support a
role in the CNS as neurotrophic factor, possibly sta-
bilizing neurons injured by deposited proteins such as
amyloid-β (Aβ) [34]. The observation that in AD GRN
is upregulated in activated microglia around amyloid
plaques further support the hypothesis of a protective
role towards a defense response to neuritic degenera-
tion [2].
Lastly, a significant association between rs9897526
and disease onset was observed in the Italian series
in term of a reduction of the age at onset in patients
carrying the rs9897526A allele. Nevertheless, the as-
sociation was not confirmed in the US series suggest-
ing that other factors such as environmental conditions
could act synergistically with the individual genetic
background to contribute to the disease.
Interestingly, a number of previous findings suggest-
ed that rs9897526 influences the age at disease onset
in different neurodegenerative diseases. In particular,
Sleegers et al. [37] examined the contribution of eight
frequent polymorphisms in risk of amyotrophic lateral
sclerosis (ALS) in a Belgian and a Dutch population,
finding three common variants in the same LD block,
including rs9897526, significantly associated with a re-
duction of age at onset and a shorter survival after onset
of ALS.
In addition, Rademakers et al. [38] demonstrated that
patients with FTLD carrying the Arg493X mutation to-
gether with the rs9897526A allele on their wild type
allele show a delayed mean age at onset of the disease.
Despite the influence of rs9897526A allele on age at
onset in this last study was opposite to our findings, the
authors reported it was not possible to draw definitive
conclusions because of the small sample size. How-
ever, the molecular mechanism at the basis of this ef-
fect is not clear yet, since rs9897526 is not located in
the splice site region and does not seem to generate an
aberrant transcript in RT-PCR; moreover, when strati-
fying patients according to the presence of rs9897526A
allele, no difference in the relative amount of mRNA
has been found. Therefore, a possible hypothesis to
be considered is that another true modifying variant
should exist in LD with rs9897526.
In conclusion, these results suggest thatGRN com-
mon variants rs5848 and rs9897526 could act as mod-
ifier factors, affecting GRN mRNA levels and possibly
decreasing the age at disease onset, likely contribut-
ing to the failure of neuronal survival. However, more
extensive functional analysis is needed to confirm this
hypothesis.
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